Article Details
Retrieved on: 2022-02-21 07:18:55
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Drugmaker AstraZeneca said on Monday that high-level results from a pivotal DESTINY-Breast04 Phase III trial showed that its Enhertu drug ...
Article found on: www.sharecast.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here